ReviewFrontiers in bioengineering and biotechnology2025
SLC26A9 in triple-negative breast cancer stem cells: a network pharmacology and molecular modeling study.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) presents significant clinical challenges due to its high heterogeneity and lack of effective targeted therapies. Cancer stem cells (CSCs) play a crucial role in TNBC recurrence, metastasis, and drug resistance. However, the interplay between ion transport, microenvironmental regulation, and classical stemness pathways remains underexplored in existing reviews. In this work, we systematically integrated multi-omics databases, network pharmacology, protein-protein interaction (PPI) analysis, functional pathway enrichment, and molecular modeling to highlight the "bridging" role of SLC26A9 and its interacting proteins in TNBC stem cell self-renewal, drug resistance, and microenvironmental regulation. Comprehensive molecular docking and 100-ns molecular dynamics (MD) simulations demonstrated that the small molecule S9-A13 exhibited high affinity and stable binding to both SLC26A9 and tumor protein p53 (TP53), with docking affinities of -7.737 and -8.447 kcal/mol and molecular mechanics/generalized Born surface area (MM/GBSA) binding free energies of -34.47 and -25.65 kcal/mol, respectively. These results suggest that S9-A13 may act on the SLC26A9-TP53 axis to enable multi-target regulation of TNBC cancer stem cells. We further discuss the translational implications of such interventions, including safety profile considerations, potential off-target effects, and delivery strategies. In summary, this review provides a structured framework and testable hypotheses for developing SLC26A9-based multi-target precision therapies for TNBC CSCs, while emphasizing that these computational findings are hypothesis-generating and require rigorous experimental and clinical validation prior to translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.